MME and heart failure: Sacubitril/valsartan (Sac/Val), an angiotensin receptor-neprilysin inhibitor (ARNI) composed of valsartan and sacubitril, has been indicated to be superior to angiotensin-converting–enzyme inhibitors (ACEI), such as enalapril, and to significantly reduce the risk of death and hospitalization in heart failure patients [5, 6].